Major interaction on record — check this product against your medications before combining. Check your meds →
Dietary supplement

Mega D-3 5000 IU & MK-7 180 mcg Ingredients & Drug Interactions

by NOW

Capsule Category: Vitamin
Most serious interaction: Major
The interaction bottom line Most serious interaction: Major

Mega D-3 5000 IU & MK-7 180 mcg is a dietary supplement by NOW with 2 active ingredients. Its ingredients are commonly taken for supporting normal blood clotting, bone health, heart and vascular health.Based on those ingredients, 715 medications have a known interaction with it, the most serious rated major. The ingredients most likely to interact are Vitamin D, Vitamin K2. Use the checker below to test your specific medication, or read the full HelloPharmacist Interaction Report.

HelloPharmacist Scorecard of Mega D-3 5000 IU & MK-7 180 mcg by NOW

Our pharmacy team’s full take, with four database checks built into the cards below — a summary of what is known, not a grade of the product itself.

From our pharmacy team — supplement deep dive

What’s inside

Full disclosure
Ingredient Transparency · database check
Full

Every active ingredient lists its own amount on the label.

Why this rating?
  • The label discloses an exact amount for 2 of its 2 active ingredients.
  • No proprietary blends here — you can verify the dose of every single component.

This product contains two active ingredients: Vitamin D at 5000 IU (a fat-soluble vitamin that supports bone health and calcium regulation) and Vitamin K2 at 180 mcg (MK-7 form, a type of vitamin K involved in bone mineralization and blood clotting). The capsule also contains three inactive ingredients — microcrystalline cellulose, hypromellose, and silicon dioxide — which are fillers and binders.

Does it work?

Strong evidence
Evidence for Intended Use · database check
By FDA rules, dietary supplements can’t claim to treat, cure, or prevent disease — so labels speak in careful marketing language. We discern each product’s intended use from its name, label claims, and label statements, then grade the clinical evidence for that use. How these ratings are computed
Strong

Clinical evidence supports at least one of this product's ingredients for its stated purpose.

Why this rating?
  • The label markets this product for: Bone, teeth, and cardiovascular health.
  • We looked for evidence on: Cardiovascular disease (CVD), Corticosteroid-induced osteoporosis, Dental caries, Fall prevention, Fractures, Hyperparathyroidism-related bone loss — and 4 related terms.
  • The strongest evidence on file: Vitamin D is rated "Effective" for Osteomalacia (Natural Medicines).
  • Also on file: Vitamin D is rated "Likely Effective" for Corticosteroid-induced osteoporosis.
  • Also on file: Vitamin D is rated "Possibly Effective" for Dental caries, Hyperparathyroidism-related bone loss.

Vitamin K2's effectiveness data in our system covers blood clotting conditions: it's rated Effective for treating hypoprothrombinemia, vitamin K-dependent clotting factor deficiency, warfarin anticoagulation, and hemorrhagic disease. It's also rated Possibly Effective for osteoporosis.

Vitamin D's documented effectiveness is for conditions like rickets, osteomalacia (soft bones), renal osteodystrophy, familial hypophosphatemia, and hypoparathyroidism — all conditions where vitamin D supplementation is clinically established. The evidence we hold doesn't cover whether this product works for general bone health or other wellness uses in otherwise healthy people.

The evidence, ingredient by ingredient Vitamin K Vitamin D

How safe is it?

Well-documented data
Safety Information · database check
Well characterized

Adverse-effect, pregnancy, and general safety data are on file for most of these ingredients.

Why this rating?
  • We hold adverse-effect (side-effect) data for 2 of the 2 matched ingredients.
  • Pregnancy & breastfeeding safety ratings cover 2 of 2.
  • General safety write-ups exist for 2 of 2.
  • Remember: this measures how much safety information exists. Thin data is not the same as being safe.

Vitamin K is generally well tolerated when taken by mouth. The most common side effects are mild and gastrointestinal — nausea, diarrhea, and stomach upset.

Vitamin D is also well tolerated at recommended doses, though very high doses over time can cause vitamin D toxicity with symptoms of high blood calcium (hypercalcemia), which can include weak bones and, in children, slowed growth. Vitamin K2 is rated Likely Safe in pregnancy and lactation.

Vitamin D's safety in pregnancy and lactation isn't detailed in our data; check with your doctor or pharmacist before use during pregnancy or breastfeeding.

Side effects, ingredient by ingredient Vitamin K Vitamin D

Meds to double-check

Major interaction found
Known Interaction Concern · database check
Major identified

At least one ingredient has a documented Major-severity interaction. Check your medications for a personalized result.

Why this rating?
  • 2 of the 2 matched ingredients can interact with medications — Vitamin D, Vitamin K.
  • The most serious interaction on file is rated Major.
  • Some involve high-stakes drug classes: anticoagulant / antiplatelet drugs; heart-rhythm medications.
  • For scale: 716 individual medications appear in the full list. A big number alone doesn't make a product dangerous — what matters is whether YOUR medication is on it, so run yours through the interaction checker on this page.

Check with your pharmacist before taking this product if you're on warfarin — vitamin K2 can reduce its blood-thinning effect. Also double-check if you take thiazide diuretics, verapamil, diltiazem, digoxin (a heart rhythm drug), or atorvastatin; vitamin D at high doses can interfere with how these work.

If you take calcipotriene (a psoriasis treatment) or have kidney disease and take aluminum-containing products, talk to your pharmacist too.

Check your own medication Run your meds through the checker above

The bottom line

Scorecard at a glanceFully disclosed formula with clinical evidence supporting its stated purpose. Major medication interactions have been identified, and safety information is well characterized.

If you take warfarin or any heart and blood pressure medication — especially thiazide diuretics, verapamil, diltiazem, or digoxin — talk to your pharmacist before starting this product. The same goes if you're on atorvastatin or any drug processed through your liver's CYP3A4 pathway.

Both ingredients are generally safe at these doses for healthy people not on those medications, but check your exact prescriptions first.

Educational only — not medical advice; always confirm with your pharmacist. Our editorial policy · How we use AI

Assessment coverage: 2 of 2 active ingredients matched to our full ingredient reviews (monographs). Based on the product label dated Jun 20, 2024.

This Scorecard evaluates available label information, ingredient evidence, and known medication-safety considerations. It does not independently verify product identity, purity, potency, contamination, or manufacturing quality. How these ratings are computed

At a glance

General information

Key facts about Mega D-3 5000 IU & MK-7 180 mcg, straight from the product label.

Brand NOW
Barcode (UPC) 733739003867
Net contents 120 Capsule(s)
Market status On market
Date entered into DSLD Jun 20, 2024
DSLD ID 313621
Product type Vitamin
Supplement form Capsule
Dietary claims / uses Nutrient, All Other, Structure/Function
Intended target group(s) Adult (18 - 50 Years), Kosher, Halal, Gluten Free, Dairy Free
From the label
Everything in this section is reproduced from the manufacturer’s own product label — it’s the label speaking, not HelloPharmacist. We show it so you can see exactly what the maker states; we don’t verify or endorse those statements.

Supplement Facts

The label details for Mega D-3 5000 IU & MK-7 180 mcg by NOW, sourced from the NIH Dietary Supplement Label Database.

Supplement Facts

Daily Value (DV) Target Group(s):
Adults and children 4 or more years of age
Minimum serving Sizes:
1 Capsule(s)
Maximum serving Sizes:
1 Capsule(s)
Servings per container
120
UPC/BARCODE
733739003867
IngredientAmount% DV
Vitamin K2180 mcg--
Vitamin D125 mcg625%

Other ingredients: Microcrystalline Cellulose, Hypromellose, Silicon Dioxide

Tap any ingredient to jump to its full detail below.

Label statements
These statements are the manufacturer’s wording, reproduced from the product label — the label is saying it, not HelloPharmacist. We don’t verify or endorse them.
Suggested/Recommended/Usage/Directions

Suggested use: Take 1 capsule daily with a fat-containing meal.

Formula

NOW Mega D-3 & MK-7 combines vitamins D-3 and K-2, two nutrients extensively researched for their roles in the health of bones, teeth, and the cardiovascular system. Vitamin D-3 works with calcium to support bone health, and more recent studies indicate it's important for immune system health as well. MenaQ7 MK-7 is a unique soy-free, bioavailable form of vitamin K-2 that plays a critical role in arterial health through its ability to support proper calcium metabolism in blood vessels and arteries. Vitamin K-2 is also important for the formation of strong, healthy bones.

Vitamins D-3 & K-2 MenaQ7

Triangle K (Kosher)

Crescent H (Halal)

FDA Disclaimer Statement

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

Precautions

Caution: For adults only.

Do not exceed the recommended dose.

Consult physician if pregnant/nursing, taking any anti-coagulants (such as warfarin, coumadin, heparin) or other medications (especially topical psoriasis medications or thiazide diuretics), or have a medical condition (especially hypercalcemia, kidney disease, or hyperparathyroidism).

Discontinue use two weeks prior to surgery.

Keep out of reach of children.

Not manufactured with wheat, gluten, soy, milk, egg, fish, shellfish, or sesame ingredients. Product in a GMP facility that processes other ingredients containing these allergens.

Formulation

Bone and cardiovascular support

Made and quality tested in the USA with globally sourced ingredients.

Not manufactured with wheat, gluten, soy, milk, egg, fish, shellfish, or sesame ingredients.

Natural color variation may occur in this product.

FDA Statement of Identity

A Dietary Supplement

Seals/Symbols

Triangle K (Kosher)

Crescent H (Halal) GMP Quality Assured

General Statements

Vitamins Family owned since 1968.

This bottle is made from 100% PCR (post-consumer recycled) resin.

Brand IP Statement(s)

MenaQ7 is a registered trademark of NattoPharma ASA, Norway. Patents granted and pending.

Storage

Store in a cool, dry place after opening.

See for yourself

Mega D-3 5000 IU & MK-7 180 mcg by NOW label

The label scan from the NIH Dietary Supplement Label Database. Tap to enlarge.

What’s inside

The Ingredients in Mega D-3 5000 IU & MK-7 180 mcg by NOW

These are the 2 active ingredients this product is made of. Select any to open its full monograph.

Serving size1 Capsule(s) Dosage formCapsule Servings per container120 Amounts shown are per serving.

Most supplement products combine several ingredients, and a medication can interact with the product through any one of them. Each ingredient below shows whether it has known drug interactions.

Vitamin K2

Interacts with
2 drugs
180 mcg per serving Form: MenaQ7

Vitamin K is an essential nutrient your body needs for normal blood clotting and to support healthy bones. Most people get enough from food, but suppl...

Vitamin K2 monograph & interactions

Vitamin D

Interacts with
715 drugs
125 mcg per serving Form: Vitamin D3

Vitamin D is a fat-soluble vitamin that helps your body absorb calcium and is important for healthy bones, muscles, and immune function. Many people,...

Vitamin D monograph & interactions

Other (inactive) ingredients: Microcrystalline Cellulose, Hypromellose, Silicon Dioxide. These complete the product’s ingredient list but are not active constituents.

Interaction report

Mega D-3 5000 IU & MK-7 180 mcg by NOW Drug Interactions

Want to check YOUR meds against Mega D-3 5000 IU & MK-7 180 mcg?

Ask about interactions with your drugs in plain English — “Can I take it with lisinopril?” — and we find you the answer in seconds, ingredient by ingredient.

Go to the checker
715Drugs
2 Major 80 Moderate 633 Minor

Ingredients driving the most interactions

Vitamin D 715

Each ingredient & the kinds of drugs it affects

For each ingredient in Mega D-3 5000 IU & MK-7 180 mcg with known interactions, here are the types of medications they can affect. Open any type for the detail — or search your exact drug in the checker above.

Vitamin D8 drug types · 715 drugs

Aluminum

Vitamin D might increase aluminum absorption and toxicity, but this has only been reported in people with renal failure.
The protein that transports calcium across the intestinal wall can also bind and transport aluminum. This protein is stimulated by vitamin D, which may therefore increase aluminum absorption. This mechanism may contribute to increased aluminum levels and toxicity in people with renal failure, when they take vitamin D and aluminum-containing phosphate binders chronically.

Likelihood Probable Evidence B
Atorvastatin (Lipitor)

Vitamin D might reduce absorption of atorvastatin.
A small, low-quality clinical study shows that taking vitamin D reduces levels of atorvastatin and its active metabolites by up to 55%. However, while atorvastatin levels decreased, total cholesterol, low-density lipoprotein (LDL) cholesterol, and high-density lipoprotein (HDL) cholesterol levels did not substantially change. Atorvastatin is metabolized in the gut by CYP3A4 enzymes, and researchers theorized that vitamin D might induce CYP3A4, causing reduced levels of atorvastatin. However, this proposed mechanism was not specifically studied.

Likelihood Probable Evidence B
Calcipotriene (Dovonex)

Taking calcipotriene with vitamin D increases the risk for hypercalcemia.
Calcipotriene is a vitamin D analog used topically for psoriasis. It can be absorbed in sufficient amounts to cause systemic effects, including hypercalcemia. Theoretically, combining calcipotriene with vitamin D supplements might increase the risk of hypercalcemia.

Likelihood Probable Evidence D
Digoxin (Lanoxin)

Theoretically, hypercalcemia induced by high-dose vitamin D can increase the risk of arrhythmia from digoxin.
High doses of vitamin D can cause hypercalcemia. Hypercalcemia increases the risk of fatal cardiac arrhythmias with digoxin. Avoid vitamin D doses above the tolerable upper intake level (4000 IU daily for adults) and monitor serum calcium levels in people taking vitamin D and digoxin concurrently.

Likelihood Possible Evidence D
Diltiazem (Cardizem, Others)

Theoretically, hypercalcemia induced by high-dose vitamin D can reduce the therapeutic effects of diltiazem for arrhythmia.
High doses of vitamin D can cause hypercalcemia. Hypercalcemia can reduce the effectiveness of verapamil in atrial fibrillation. Theoretically this could also occur with diltiazem. Avoid vitamin D doses above the tolerable upper intake level (4000 IU daily for adults) and monitor serum calcium levels in people taking vitamin D and diltiazem concurrently.

Likelihood Probable Evidence B
Thiazide Diuretics

Theoretically, taking thiazide diuretics and high-dose vitamin D can increase the risk of hypercalcemia.
Thiazide diuretics decrease urinary calcium excretion, which could lead to hypercalcemia if vitamin D supplements are taken concurrently. This has been reported in people being treated with vitamin D for hypoparathyroidism, and also in elderly people with normal parathyroid function who were taking a thiazide, vitamin D, and calcium-containing antacids daily.

Likelihood Probable Evidence D
Verapamil (Calan, Others)

Hypercalcemia induced by high-dose vitamin D can reduce the therapeutic effects of verapamil for arrhythmia.
Hypercalcemia due to high doses of vitamin D can reduce the effectiveness of verapamil in atrial fibrillation. Avoid vitamin D doses above the tolerable upper intake level (4000 IU daily for adults) and monitor serum calcium levels in people taking vitamin D and verapamil concurrently.

Likelihood Probable Evidence B
Cytochrome P450 3A4 (Cyp3A4) Substrates

Vitamin D might induce CYP3A4 enzymes and reduce the bioavailability of CYP3A4 substrates.
There is some concern that vitamin D might induce CYP3A4. In vitro research suggests that vitamin D induces CYP3A4 transcription. Additionally, observational research has found that increased UV light exposure and serum vitamin D levels are associated with decreased serum levels of CYP3A4 substrates such as tacrolimus and sirolimus, while no association between UV light exposure or vitamin D levels and levels of mycophenolic acid, a non-CYP3A4 substrate, was found. A small, low-quality clinical study shows that taking vitamin D reduces levels of the CYP3A4 substrate atorvastatin and its active metabolites by up to 55%; however, the clinical effects of atorvastatin were not reduced. While researchers theorized that vitamin D might induce CYP3A4, this proposed mechanism was not specifically studied.

Likelihood Possible Evidence D

Vitamin K21 drug type · 2 drugs

Warfarin (Coumadin)

Vitamin K can antagonize and reverse the therapeutic effects of warfarin.
Vitamin K antagonizes the effects of warfarin. Excessive vitamin K intake, either from supplements or from changes in the diet, can reduce the anticoagulant effect of warfarin.

Likelihood Likely Evidence C
The maker

Brand information

Manufacturer and brand details for Mega D-3 5000 IU & MK-7 180 mcg, from the product label.

NOW

See all NOW products
Name
NOW FOODS
Street Address
395 S. Glen Ellyn Rd.
City
Bloomingdale
State
IL
ZipCode
60108
Web Address
nowfoods.com
Pharmacist Counseling Corner

Mega D-3 5000 IU & MK-7 180 mcg by NOW: Common Questions

Does Mega D-3 5000 IU & MK-7 180 mcg by NOW interact with any medications?
Yes. Based on its ingredients, Mega D-3 5000 IU & MK-7 180 mcg has a known interaction with 715 medications, including 2 rated major. Use the checker to see how it interacts with a specific drug.
How can one product interact with so many drugs?
Mega D-3 5000 IU & MK-7 180 mcg contains 2 active ingredients, and an interaction can come from any of them. We check every ingredient, combine the results into one list per medication, and show which ingredient and mechanism is responsible.
Where does this information come from?
The product label data comes from the NIH Dietary Supplement Label Database (DSLD); the interaction data is built on the Natural Medicines database and reviewed by HelloPharmacist pharmacists.
Can I take this if I'm pregnant?
Vitamin K2 is rated Likely Safe in pregnancy. Vitamin D doesn't have a pregnancy rating in our data, so there isn't enough information to know. Talk to your doctor or pharmacist before you start — they can give you personalized advice based on your health and how much vitamin D you already get.
Can I take this if I'm breastfeeding?
Our data shows Vitamin K2 is Likely Safe during breastfeeding. We don't have a lactation rating for Vitamin D, so talk to your doctor or pharmacist about whether it's right for you while breastfeeding.
What are the side effects?
Vitamin K is generally well tolerated; mild gastrointestinal upset — nausea, diarrhea, stomach upset — is the most common. Vitamin D is also well tolerated at this dose. Very high doses of either ingredient over time can cause problems, but this 5000 IU D dose is below the upper safe limit for adults (4000 IU daily).
Does this product have fillers?
Yes, it contains three inactive ingredients: microcrystalline cellulose, hypromellose, and silicon dioxide — standard binders and fillers used in capsules.
What is MK-7?
MK-7 is a form of Vitamin K2, a version of vitamin K that your body uses for bone mineralization and blood clotting. It's one of the most absorbable forms.
Can I take this for general bone health?
Our data shows Vitamin K2 is Possibly Effective for osteoporosis, and Vitamin D does support bone health — that's well established. But the specific benefits of this combination for overall bone health in people without a deficiency aren't detailed in the evidence we hold. Talk to your doctor about whether it's right for your situation.

Written and reviewed by the HelloPharmacist editorial staff. Our editorial policy

Not sure if Mega D-3 5000 IU & MK-7 180 mcg is safe with your meds?

Our pharmacists answer your medication & supplement questions — free.

Ask a pharmacist

Label information is sourced from the NIH Dietary Supplement Label Database and reflects the product version on file; always read your actual product label. This page is for education only and is not a substitute for professional medical advice. Confirm with your pharmacist or doctor before combining supplements and medications.

Mega D-3 5000 IU & MK-7 180 mcg label
Sources

Sources & How We Checked

Mega D-3 5000 IU & MK-7 180 mcg's label data comes from the NIH Dietary Supplement Label Database; the ingredient interaction data is from the Natural Medicines database, reviewed by our pharmacists.

Content is written and reviewed by licensed HelloPharmacist pharmacists. See our data sources and editorial standards for how this information is built and checked.

The 37 references behind this product’s interaction data

Every citation that drives the interaction findings for this product’s ingredients, from the evidence-graded Natural Medicines (TRC Healthcare) database. Open an ingredient to browse its citations — links open the study on PubMed or the publisher’s site.

Vitamin K 11 references
  1. McEvoy GK, ed. AHFS Drug Information. Bethesda, MD: American Society of Health-System Pharmacists, 1998.
  2. Food and Nutrition Board, Institute of Medicine. Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, and Zinc. Washington, DC: National Academy Press, 2002.
  3. Crowther MA, Ageno W, Garcia D, et al. Oral vitamin K versus placebo to correct excessive anticoagulation in patients receiving warfarin: a randomized trial. Ann Intern Med. 2009;150(5):293-300. PubMed
  4. Dietary vitamin K guidance: an effective strategy for stable control of oral anticoagulation? Nutr Rev. 2010;68(3):178-81. PubMed
  5. Kim JS, Nafziger AN, Gaedigk A, et al. Effects of oral vitamin K on S- and R-warfarin pharmacokinetics and pharmacodynamics: enhanced safety of warfarin as a CYP2C9 probe. J Clin Pharmacol. 2001 Jul;41(7):715-22. PubMed
  6. Riegert-Johnson, D. L. and Volcheck, G. W. The incidence of anaphylaxis following intravenous phytonadione (vitamin K1): a 5-year retrospective review. Ann.Allergy Asthma Immunol. 2002;89(4):400-406. PubMed
  7. Dezee, K. J., Shimeall, W. T., Douglas, K. M., Shumway, N. M., and O'malley, P. G. Treatment of excessive anticoagulation with phytonadione (vitamin K): a meta-analysis. Arch.Intern.Med. 2-27-2006;166(4):391-397. DOI
  8. Dentali, F., Ageno, W., and Crowther, M. Treatment of coumarin-associated coagulopathy: a systematic review and proposed treatment algorithms. J.Thromb.Haemost. 2006;4(9):1853-1863. PubMed
  9. Caluwé R, Vandecasteele S, Van Vlem B, Vermeer C, De Vriese AS. Vitamin K2 supplementation in haemodialysis patients: a randomized dose-finding study. Nephrol Dial Transplant. 2014;29(7):1385-90.
  10. Huang ZB, Wan SL, Lu YJ, Ning L, Liu C, Fan SW. Does vitamin K2 play a role in the prevention and treatment of osteoporosis for postmenopausal women: a meta-analysis of randomized controlled trials. Osteoporos Int. 2015;26(3):1175-86. PubMed
  11. Hunnali CR, Devi U, Kitchanan S, Sethuraman G. Three Different Regimens for Vitamin K Birth Prophylaxis in Infants Born Preterm: A Randomized Clinical Trial. J Pediatr 2023;255:98-104. PubMed

See these in context on the Vitamin K monograph →

Vitamin D 26 references
  1. McEvoy GK, ed. AHFS Drug Information. Bethesda, MD: American Society of Health-System Pharmacists, 1998.
  2. Tatro DS, ed. Drug Interactions Facts. Facts and Comparisons Inc., St. Louis, MO. 1999.
  3. Koutkia P, Chen TC, Holick MF. Vitamin D intoxication associated with an over-the-counter supplement. N Engl J Med 2001;345:66-7. PubMed
  4. Bar-Or D, Yoel G. Calcium and calciferol antagonize effect of verapamil in atrial fibrillation. Br Med J 1981;282:1585-6.
  5. Demontis R, Leflon A, Fournier A, et al. 1 alpha(OH) vitamin D3 increases plasma aluminum in hemodialyzed patients taking AI(OH)3. Clin Nephrol 1986;26:146-9.
  6. Crowe M, Wollner L, Griffiths RA. Hypercalcemia following vitamin D and thiazide therapy in the elderly. Practitioner 1984;228:312-3.
  7. Parfitt AM. Thiazide-induced hypercalcemia in vitamin D-treated hypoparathyroidism. Ann Intern Med 1972;77:557-63. PubMed
  8. Thiazide diuretics and the risk of osteoporosis. Pharmacist's Letter/Prescriber's Letter 2003;19(11):191105.
  9. Moon J. The role of vitamin D in toxic metal absorption. J Am Coll Nutr 1994;13:559-64.
  10. Demontis R, Reissi D, Noel C, et al. Indirect clinical evidence that 1alphaOH vitamin D<SUB>3</SUB> increases the intestinal absorption of aluminum. Clin Nephrol 1989;31:123-7.
  11. Adler AJ, Berlyne GM. Duodenal aluminum absorption in the rat: effect of vitamin D. Am J Physiol 1985;249:G209-13. PubMed
  12. Schwartz JB. Effects of vitamin D supplementation in atorvastatin-treated patients: A new drug interaction with an unexpected consequence. Clin Pharmacol Ther 2009;85:198-203. PubMed
  13. Dietary reference intakes for calcium and vitamin D. Institute of Medicine, November 30, 2010. Available at: http://www.iom.edu/~/media/Files/Report%20Files/2010/Dietary-Reference-Intakes-for-Calcium-and-Vitamin-D/Vitamin%20D%20and%20Calcium%202010%20Repo
  14. Cox KA, Dunn MA. Aluminum toxicity alters the regulation of calbindin-D28k protein and mRNA expression in chick intestine. J Nutr 2001;131:2007-13. PubMed
  15. Escribano, J., Balaguer, A., Pagone, F., Feliu, A., and Roque, I. Figuls. Pharmacological interventions for preventing complications in idiopathic hypercalciuria. Cochrane.Database.Syst.Rev. 2009;(1):CD004754. PubMed
  16. Carlton, S., Clopton, D., and Cappuzzo, K. A. Vitamin D deficiency: appropriate replenishment therapies and the effects of vitamin D toxicity. Consult Pharm 2010;25(3):171-177. PubMed
  17. Wang, H., Xia, N., Yang, Y., and Peng, D. Q. Influence of vitamin D supplementation on plasma lipid profiles: a meta-analysis of randomized controlled trials. Lipids Health Dis. 2012;11:42. PubMed
  18. Turner AN, Carr Reese P, Fields KS, Anderson J, Ervin M, Davis JA, Fichorova RN, Roberts MW, Klebanoff MA, Jackson RD. A blinded, randomized controlled trial of high-dose vitamin D supplementation to reduce recurrence of bacterial vaginosis. Am J Obstet G PubMed
  19. Weiner M, Epstein FH. Signs and symptoms of electrolyte disorders. Yale J Biol Med. 1970;43(2):76-109.
  20. Lappe J, Watson P, Travers-Gustafson D, Recker R, Garland C, Gorham E, Baggerly K, McDonnell SL. Effect of Vitamin D and Calcium Supplementation on Cancer Incidence in Older Women: A Randomized Clinical Trial. JAMA. 2017 Mar 28;317(12):1234-1243. PubMed
  21. Roth DE, Leung M, Mesfin E, Qamar H, Watterworth J, Papp E. Vitamin D supplementation during pregnancy: state of the evidence from a systematic review of randomised trials. BMJ. 2017;359:j5237. PubMed
  22. Murai IH, Fernandes AL, Sales LP, et al. Effect of a single high dose of vitamin D3 on hospital length of stay in patients with moderate to severe COVID-19: A randomized clinical trial. JAMA. 2021.
  23. Wang Z, Schuetz EG, Xu Y, Thummel KE. Interplay between vitamin D and the drug metabolizing enzyme CYP3A4. J Steroid Biochem Mol Biol 2013;136:54-8. PubMed
  24. Doyle D, Browne U, Brickley A, Murphy D. Vitamin D-induced hypercalcaemia and acute kidney injury in sarcoidosis. BMJ Case Rep 2023;16(1):e250580. PubMed
  25. Williamson A, Martineau AR, Sheikh A, Jolliffe D, Griffiths CJ. Vitamin D for the management of asthma. Cochrane Database Syst Rev 2023;2(2):CD011511. PubMed
  26. Kinesya E, Santoso D, Gde Arya N, et al. Vitamin D as adjuvant therapy for diabetic foot ulcers: Systematic review and meta-analysis approach. Clin Nutr ESPEN 2023;54:137-143. PubMed

See these in context on the Vitamin D monograph →

Parts of this content are provided by the Therapeutic Research Center, LLC.

DISCLAIMER: Currently this does not check for drug-drug interactions. This is not an all-inclusive comprehensive list of potential interactions and is for informational purposes only. Not all interactions are known or well-reported in the scientific literature, and new interactions are continually being reported. Input is needed from a qualified healthcare provider including a pharmacist before starting any therapy. Application of clinical judgment is necessary.

© 2021 Therapeutic Research Center, LLC

Keep exploring